Methylphenidate Oral Solution

University of California, Davis · FDA-approved active Small molecule

Methylphenidate Oral Solution is a Sympathomimetic amine; CNS stimulant Small molecule drug developed by University of California, Davis. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy. Also known as: MPH, Ritalin, Concerta, Jornay PM.

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.

At a glance

Generic name	Methylphenidate Oral Solution
Also known as	MPH, Ritalin, Concerta, Jornay PM, Biphentin®
Sponsor	University of California, Davis
Drug class	Sympathomimetic amine; CNS stimulant
Target	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Modality	Small molecule
Therapeutic area	Neurology; Psychiatry
Phase	FDA-approved

Mechanism of action

Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The oral solution formulation allows for flexible dosing and is particularly useful in pediatric populations or patients with difficulty swallowing tablets.

Approved indications

• Attention-deficit/hyperactivity disorder (ADHD)
• Narcolepsy

Common side effects

• Insomnia
• Decreased appetite
• Headache
• Nervousness or anxiety
• Abdominal pain
• Tachycardia
• Elevated blood pressure

Key clinical trials

• Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities (PHASE1)
• Cannabidiol and CES1 Interactions in Healthy Subjects (PHASE4)
• Treatment of Orthostatic Hypotension in Autonomic Failure (PHASE1)
• Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Methylphenidate Oral Solution CI brief — competitive landscape report
• Methylphenidate Oral Solution updates RSS · CI watch RSS
• University of California, Davis portfolio CI

Frequently asked questions about Methylphenidate Oral Solution

What is Methylphenidate Oral Solution?

Methylphenidate Oral Solution is a Sympathomimetic amine; CNS stimulant drug developed by University of California, Davis, indicated for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.

How does Methylphenidate Oral Solution work?

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.

What is Methylphenidate Oral Solution used for?

Methylphenidate Oral Solution is indicated for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.

Who makes Methylphenidate Oral Solution?

Methylphenidate Oral Solution is developed and marketed by University of California, Davis (see full University of California, Davis pipeline at /company/university-of-california-davis).

Is Methylphenidate Oral Solution also known as anything else?

Methylphenidate Oral Solution is also known as MPH, Ritalin, Concerta, Jornay PM, Biphentin®.

What drug class is Methylphenidate Oral Solution in?

Methylphenidate Oral Solution belongs to the Sympathomimetic amine; CNS stimulant class. See all Sympathomimetic amine; CNS stimulant drugs at /class/sympathomimetic-amine-cns-stimulant.

What development phase is Methylphenidate Oral Solution in?

Methylphenidate Oral Solution is FDA-approved (marketed).

What are the side effects of Methylphenidate Oral Solution?

Common side effects of Methylphenidate Oral Solution include Insomnia, Decreased appetite, Headache, Nervousness or anxiety, Abdominal pain, Tachycardia.

What does Methylphenidate Oral Solution target?

Methylphenidate Oral Solution targets Dopamine transporter (DAT); Norepinephrine transporter (NET) and is a Sympathomimetic amine; CNS stimulant.

Related

• Drug class: All Sympathomimetic amine; CNS stimulant drugs
• Target: All drugs targeting Dopamine transporter (DAT); Norepinephrine transporter (NET)
• Manufacturer: University of California, Davis — full pipeline
• Therapeutic area: All drugs in Neurology; Psychiatry
• Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD)
• Indication: Drugs for Narcolepsy
• Also known as: MPH, Ritalin, Concerta, Jornay PM, Biphentin®